Medical device company Creo Medical Group plc (AIM: CREO) on Wednesday announced the commencement of the first robotic-guided microwave ablation procedures for cancerous lung tissue at a leading UK hospital.
This follows an amendment to the company's collaboration with Intuitive, announced in July 2024, which integrates Creo's MicroBlate Flex ablation device with Intuitive's Ion Endoluminal System.
The hospital is the second UK site to perform such procedures, joining Royal Brompton Hospital, which began similar operations as part of an ongoing clinical study led by Professor Shah. The procedures are part of the Pioneer Programme, which will continue to gather clinical evidence throughout 2025 before transitioning to a commercial phase. Creo expects the number of procedures to increase within the current year.
Creo Medical specialises in developing minimally invasive electrosurgical devices for cancer treatment, including its CROMA system powered by Kamaptive technology. This advanced energy platform enables precise tissue manipulation for resection, dissection, coagulation and ablation, offering increased flexibility, precision and control in surgical procedures.
Acrivon Therapeutics receives FDA Breakthrough Device designation for ACR-368 OncoSignature assay
Vistagen secures US patent for AV-101 in neuropathic pain treatment
Thermo Fisher Scientific launches international registry for adolescent alopecia areata
hVIVO successfully completes RSV antiviral trial for Shionogi
Valneva secures UK approval for world's first chikungunya vaccine
Alys Pharmaceuticals' IND for ALY-101 approved in US and Canada
NeuroTherapia's Phase 2 Alzheimer's disease trial receives European regulatory approval
NFL Biosciences confirms superior safety profile of NFL-101 in new toxicity study
Avirmax Biopharma completes first cohort of Wet AMD clinical trial
PhaseV collaborates with Alimentiv to address challenges in GI clinical trials
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Helix unveils clinico-genomic dataset of over 15,000 patients treated with GLP-1 agonists
Roquefort Therapeutics sells Lyramid for USD10.8m equity deal with Pleiades Pharma